Related Experiment Videos
Clinical experience with fludarabine in leukaemia
M J Keating1, E Estey, S O'Brien
1University of Texas M.D. Anderson Cancer Center, Houston.
Drugs
|January 1, 1994
Summary
Fludarabine is effective for chronic lymphocytic leukemia (CLL) at lower doses, showing significant remission rates. Higher doses caused neurotoxicity, but lower doses are safe and beneficial for CLL management.
Area of Science:
- Oncology
- Pharmacology
Background:
- Fludarabine (Fludara) is a purine analogue investigated since 1982.
- Initial high-dose studies in acute leukemia revealed significant efficacy but severe neurotoxicity.
Purpose of the Study:
- To evaluate the safety and efficacy of lower-dose fludarabine regimens.
- To establish the role of fludarabine in managing chronic lymphocytic leukemia (CLL).
Main Methods:
- Administered lower doses (25-30 mg/m2/day for 5 days) in chronic lymphocytic leukemia (CLL) and low-grade lymphomas.
- Assessed response rates and toxicity profiles, including neurotoxicity and myelosuppression.
Main Results:
- Lower doses of fludarabine demonstrated effectiveness and safety in CLL, with minimal neurotoxicity.
- Over 50% response rates, with two-thirds complete remissions, were observed in previously treated CLL patients.
- Infections and febrile episodes were the primary morbidities in CLL patients, particularly those previously treated or with advanced disease.
Conclusions:
- Fludarabine is a key treatment for CLL, with lower doses offering a favorable risk-benefit profile.
- Combination therapies like FA and FLAG regimens show promise for acute leukemias and myelodysplastic syndromes.
- Fludarabine's diverse activities suggest a growing role in future leukemia treatment combinations.